These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25010019)

  • 1. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice.
    Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R
    Neurosci Lett; 2014 Aug; 578():187-91. PubMed ID: 25010019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
    Zhang RS; He Z; Jin WD; Wang R
    Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice.
    Pan JX; Wang ZL; Li N; Zhang N; Wang P; Tang HH; Zhang T; Yu HP; Zhang R; Zheng T; Fang Q; Wang R
    Eur J Pharmacol; 2015 Nov; 767():119-25. PubMed ID: 26472125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
    Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
    J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.
    Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R
    Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB
    Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
    Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
    Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
    Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
    Wang P; Zheng T; Zhang M; Xu B; Zhang R; Zhang T; Zhao W; Shi X; Zhang Q; Fang Q
    Brain Res Bull; 2018 May; 139():48-55. PubMed ID: 29425797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
    Hama A; Sagen J
    Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
    Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
    Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptide VF Enhances Cannabinoid Agonist WIN55,212-2-Induced Antinociception in Mice.
    Han ZL; Wang ZL; Li XH; Li N; Pan JX; Zheng T; Fang Q; Wang R
    Anesth Analg; 2015 Nov; 121(5):1360-8. PubMed ID: 26273748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
    Fang Q; Han ZL; Li N; Wang ZL; He N; Wang R
    Neuropharmacology; 2012 Feb; 62(2):855-64. PubMed ID: 21945715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 Cannabinoid Agonist (WIN55,212-2) Within the Basolateral Amygdala Induced Sensitization to Morphine and Increased the Level of μ-Opioid Receptor and c-fos in the Nucleus Accumbens.
    Molaei M; Fatahi Z; Zaringhalam J; Haghparast A
    J Mol Neurosci; 2016 Apr; 58(4):446-55. PubMed ID: 26803309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-accumbal NMDA but not AMPA/kainate receptor antagonist attenuates WIN55,212-2 cannabinoid receptor agonist-induced antinociception in the basolateral amygdala in a rat model of acute pain.
    Ghalandari-Shamami M; Hassanpour-Ezatti M; Haghparast A
    Pharmacol Biochem Behav; 2011 Dec; 100(2):213-9. PubMed ID: 21924283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supraspinal interaction between HIV-1-gp120 and cannabinoid analgesic effectiveness.
    Palma J; Narasimhan M; Guindon J; Benamar K
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1157-1161. PubMed ID: 30008083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical cannabinoid antinociception: synergy with spinal sites.
    Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
    Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.
    Nealon CM; Henderson-Redmond AN; Hale DE; Morgan DJ
    Neuropharmacology; 2019 Apr; 148():151-159. PubMed ID: 30629988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.
    Dodd GT; Mancini G; Lutz B; Luckman SM
    J Neurosci; 2010 May; 30(21):7369-76. PubMed ID: 20505104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
    Elmas P; Ulugol A
    J Neural Transm (Vienna); 2013 Nov; 120(11):1533-8. PubMed ID: 23784345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.